A total investment of 1.57 billion yuan!Midi Northwest Shanghai Biomedical R & D Innovation Industrial Base Project started in Baoshan

On September 21, a total investment of 1.57 billion yuan, covering an area of ​​66.9 acres, and a total construction area of ​​more than 150,000 square meters, the Northwest Shanghai Biomedical R & D and Innovation Industry Base Project, in the core area of ​​Biopharmaceutical Industrial Park, North Shanghai The foundation was laid out.

The project is located on the north side of Panjing Road and Yueluo Road in Baoshan District, Shanghai. After completion Synthetic platforms, antibody drug puppet couplet (ADC) R & D platform, biological research platform, etc., establish a one -stop drug research and development platform with domestic new drug research and innovation capabilities, explore and form a higher -level pharmaceutical research and development scientific support and experiments Room research and development pillars.

"We landed in Baoshan is a large platform for biomedical research and development service. It is another milestone project for the development of the CRO+CDMO chain. Among them, 100,000 square meters are used for new drug research and development services. I hope to drive more biomedical research and development Enterprises settled in Baoshan to help companies develop higher quality and invest in clinical trials faster. "Said Chen Chunlin, founder and CEO of Midi, said.

This year is the key year of Baoshan's development. The Twelfth Party Congress of the Municipal Association has given the main position of the main position of Baoshan Construction Science and Technology Innovation Center and the green low -carbon transformation model area. As an important starting point, North Shanghai Biomedical Industrial Park is accelerating the creation of a global influential biomedical industry cluster. Zhai Lei, the deputy district, said that the landing of the Midi Si New project will be an important part of the development of the Baoshan full -chain biomedical industry, becoming the key force of Baoshan to build the main position of the science and technology innovation center.

At the ceremony, Midixi signed a strategic cooperation agreement with colleges and universities and pharmaceutical companies such as the Shanghai University Medical College, Aibo Biology, He Platinum Medicine, Pharmaceutical Bio and other universities and pharmaceutical companies, and donated 1.5 million yuan to Shanghai University to set up the Meidixi Education Development Fund. It aims to support the construction of education infrastructure in Shanghai University, stimulate students' scientific research and innovation capabilities, cultivate talents in the domestic biomedical industry, and promote the vigorous development of biomedical disciplines.

According to reports, the project starts from intended investment to landing, overcome the adverse impact of the epidemic, continues to accelerate, and realize "starting land". On September 20th, in order to fully promote the construction of major industrial projects in the district, the Platform Planning Resources Bureau of Baoshan District issued the "Construction Engineering Design Plan", "Construction Land Planning License", "Construction Engineering Planning" to the Midixi Project. "License" "Construction Project Construction License" realizes the "four certificates issued" on the same day.

Luodian Town stated that it will continue to give the enterprise's full life cycle support: "We will fully use 30 policies of science and technology innovation in Baoshan District, especially the Pokémon 'Biomedical 2.0 version' heavy policy, and give full support for the development of the United States. Do a series of comprehensive services such as funds, talents, policies, resources, etc. "

Founded in 2004, Midi, headquartered in Shanghai, is committed to providing a full range of pre -clinical new drug research services for global pharmaceutical companies, research institutions and scientific researchers. The one -stop comprehensive service of Midicei uses strong project management and more efficient and cost -effective R & D services to help customers accelerate the development process of new drug research and development, and serve the entire process of new drug research on pharmaceutical clinical drugs, including drug discovery, pharmacy research, and clinical clinical practice. Previous research. By the end of the semi -annual report of 2022, Medici had provided new drug research and development services to more than 1,710 customers worldwide, and 268 INDs participated in the research and development of 268 Indoisisa were approved clinically.

In March 2020, North Shanghai Biomedical Industrial Park was officially awarded as one of the five municipal -level characteristic biomedical industrial parks in Shanghai. From the initial sporadic layout of the enterprise, to the current head camp formed, the park has attracted more than 200 various types Biomedical enterprises have settled in and further formed an industrial ecosystem of "R & D, production, and service".

Source: Shanghai Baoshan official WeChat

- END -